Bio-tech company Transcell Biologics has secured an undisclosed amount of funding from Boston-based Quantiphi and IAN Group. The investment will be utilized to expand its client base and implement Digital Animal Replacement Technology (DART) as an enterprise solution for the global bio and pharmaceutical industries.
Founded in 2009 by Subadra Dravida, Transcell Biologics specializes in optimizing stem cell yield while maintaining pluripotency and functionality. The company has developed a proprietary process, extending the application of its stem cell technologies.
The Hyderabad-based firm’s DART solution provides an animal-free testing platform that combines human MicroPhysiological Systems (hMPS) with AI and machine learning. This technology automates bioassay processes and generates statistically compliant reports, ensuring safety and efficacy testing for drugs and vaccines.
DART has gained significant traction in India, with major biopharmaceutical companies integrating it into their high-impact programs. Transcell Biologics plans to further expand into markets in the USA, Europe, and Japan.